BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

PolTREG's Treg Cell Therapy Achieves Long-Term Clinical Remission and Insulin Independence in Type 1 Diabetes Patients

NextEdge Admin

09 Sep 2024

2 min 23 sec

PolTREG S.A. , a clinical-stage biotechnology company focused on developing cellular therapies for autoimmune diseases, announced promising long-term data from its Treg cell therapy, PTG-007, for patients with type-1 diabetes (T1D). Results showed that some patients achieved clinical remission for up to 12 years, with a subset remaining insulin-independent for 18 to 24 months post-treatment. The data will be presented at the INNODIA EASD symposium in Madrid.

“Type-1 diabetes requires a life-long commitment to care. Our results show that PTG-007 offers a path to long-term clinical remission, freeing some patients from the daily burden of insulin injections,” said Prof Piotr Trzonkowski, CEO of PolTREG.

The study followed 54 patients from Phase I and II trials, monitoring their outcomes over a period of 7 to 12 years. Key findings included sustained insulin independence for some patients and clinical remission defined as minimal insulin requirements with effective metabolic control. Patients who received Treg therapy combined with anti-CD20 treatment (rituximab) showed the best results.

The study analyzed over 700 variables across multiple organ systems and found no significant differences compared to standard-of-care, with no severe adverse effects reported. PolTREG plans to publish these findings in a peer-reviewed journal.

PolTREG’s Treg therapy pipeline is one of the largest for autoimmune diseases. PTG-007 is currently in mid-stage clinical trials for T1D and multiple sclerosis, with upcoming studies planned for presymptomatic T1D and engineered CAR-Treg therapies for multiple sclerosis and amyotrophic lateral sclerosis.